Evidence map›Paper›PMID 31232238›Full record

ArticleMicroRNA (Shariqah, United Arab Emirates)2020

Hotspot Mutations in DICER1 Causing GLOW Syndrome-Associated Macrocephaly

Steven D Klein, Julian A Martinez-Agosto

Open access · hybridAbstract read
In one paragraph

Article in MicroRNA (Shariqah, United Arab Emirates), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Rare Hereditary Gynecological Cancer Syndromes.International journal of molecular sciences · 2022
    Review
  12. ETMR: a tumor entity in its infancy.Acta neuropathologica · 2020
    Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Steven D KleinDepartment of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, California, United States.
Julian A Martinez-AgostoDepartment of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, California, United States.
University of California, Los Angeles · US

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Understanding Repetitive Behavior in AutismP50HD055784 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BOOKHEIMER, SUSAN Y · 2007 to 2021
$32.0M
UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
UCLA Center for Translational Research in Neurodevelopment: UC-TRaNU54HD087101 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCCRACKEN, JAMES T. · 2016 to 2020
$6.5M
NCATS NIH HHS UL1 TR000124NICHD NIH HHS P50 HD055784NICHD NIH HHS U54 HD087101NIGMS NIH HHS T32 GM008042
6 · The paper itself

Abstract

backgroundWe have previously described mosaic mutations in the RNase IIIb domain of DICER1that display global developmental delays, lung cysts, somatic overgrowth, macrocephaly and Wilms tumor. This constellation of phenotypes was classified as GLOW syndrome. Due to the phenotypic overlap between GLOW and syndromes caused by mutations in the PI3K/AKT/mTOR pathway, we hypothesized that alterations in miRNA regulation of this pathway cause its specific constellation of phenotypes.

objectiveTo test the hypothesis that DICER1 "hot spot" mutations associated with GLOW syndrome activate PI3K/AKT/mTOR signaling.

methodsWe developed HEK293T cells with loss of exon 25 in DICER1, a genetic modification that is synonymous with the "hot spot" RNAseIIIb mutations that cause GLOW syndrome. We assayed the cells for activation of the PI3K/AKT/mTOR signaling pathway.

resultsWe observed activation of the PI3K/AKT/mTOR pathway as demonstrated by increased pS6Kinase, p4EBP1 and pTSC2 levels. Additionally, these cells demonstrate a striking cellular phenotype, with the ability to form spheres when the serum is removed from their growth medium. The cells in these spheres are Oct4 and Sox2 positive and exhibit the property of reversion with the addition of serum. We queried miRNA expression data and identified a population of miRNAs that increase due to these mutations and target negative regulators of the PI3K/AKT/mTOR pathway.

conclusionThis work identifies the delicate and essential role for miRNA control of the PI3K/AKT/mTOR pathway. We conclude that the phenotypes observed in the GLOW syndrome are the result of PI3K/AKT/mTOR activation.

Indexed as

Cell LineDEAD-box RNA HelicasesHEK293 CellsHumansKidney NeoplasmsMegalencephalyMicroRNAsOctamer Transcription Factor-3Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRibonuclease IIIRibosomal Protein S6 KinasesSignal TransductionSOXB1 Transcription FactorsTOR Serine-Threonine KinasesTuberous Sclerosis Complex 2 ProteinDEAD-box RNA HelicasesDICER1 protein, humanMicroRNAsMTOR protein, humanOctamer Transcription Factor-3Phosphatidylinositol 3-KinasesPOU5F1 protein, humanProto-Oncogene Proteins c-aktRibonuclease IIIRibosomal Protein S6 KinasesSOX2 protein, humanSOXB1 Transcription FactorsTOR Serine-Threonine KinasesTSC2 protein, humanTuberous Sclerosis Complex 2 ProteinCancerDICER1hot spotmicoRNAovergrowth.PI3K/AKT/mTOR

Identifiers

PMID31232238
PMCPMC8405056
OpenAlexW2954161366

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.